The blood grouping reagents for extended phenotype testing cover more than 99 percent of the most commonly tested blood-group antigens.  

The assay can also be used to assess a broad range of metabolic conditions, including pancreatic tumors, liver disease, acromegaly, and others.  

The arrangement will allow Illumina to market and promote Kailos' research solutions for pharmacogenetic target enrichment.